ChronoScale Corporation Common Stock Q1 2026 Earnings Report

ChronoScale Corporation Common Stock EPS Results

• Actual EPS: -$2.04
• Consensus EPS: -$0.03
• Beat/Miss: Missed by -$2.01
• One Year Ago EPS: N/A

ChronoScale Corporation Common Stock Revenue Results

• Actual Revenue: $2.14 million
• Expected Revenue: $4.29 million
• Beat/Miss: Missed by -$2.15 million
• YoY Revenue Growth: N/A

ChronoScale Corporation Common Stock Announcement Details

• Quarter: Q1 2026
• Date: 4/28/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, April 28, 2026
• Conference Call Time: 4:00PM ET

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.